Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Obamacare Whiplash Leaves States, Insurers with Dueling Price Plans

Caroline Humer  |  October 22, 2017

NEW YORK (Reuters)—President Donald Trump’s reversals in the past week on maintaining Obamacare subsidies to insurers are sowing new confusion over what kind of health insurance will be available to consumers, and at what price, when enrollment for 2018 begins in two weeks. Trump said last week his administration would stop paying billions of dollars…

Biosimilar Infliximab Appears Safe, Effective in Pediatric IBD

Reuters Staff  |  October 22, 2017

NEW YORK (Reuters Health)—A biosimilar version of infliximab appears as effective as the original for treating pediatric inflammatory bowel disease (PIBD), and less costly, new research shows. “These baseline data have now enabled us to confidently switch patients from originator to biosimilar, adopting the same prospective methodology to monitor effectiveness, safety and cost,” Dr. Lisa…

Where OA & Depression Intersect

Carina Stanton  |  October 20, 2017

Pain, limited mobility and lower quality of life—these aspects of living with osteoarthritis may result in severe depression. New research from Alan Rathbun, PhD, MPH, may enable physicians to better understand the intersection of physical and mental health so they can improve overall patient care…

Novartis to Shut U.S. Generics Plant, Cut 450 Jobs

Reuters Staff  |  October 19, 2017

ZURICH (Reuters)—Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures. “To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated…

Some Middle-Class Americans Worry Trump Health Subsidies Cut Will Hurt

Tim Reid and Yasmeen Abutaleb  |  October 19, 2017

PHILADELPHIA (Reuters)—Tom Westerman voted for Donald Trump in last year’s election but says he might not do so again after the president cut off billions of dollars in Obamacare subsidies to health insurance companies. “It really upset me,” said Westerman, 63, a self-described “middle-class guy” with an annual household income of about $60,000 in the…

Do Older Women Who Use Bisphosphonates Need Fewer Knee Replacements?

Reuters Staff  |  October 19, 2017

NEW YORK (Reuters Health)—The rate of knee replacement surgery among older women with knee osteoarthritis is lower in those who take bisphosphonates than in those who don’t, according to a database study. Knee osteoarthritis accounts for 97% of all knee replacement surgeries. Trials of bisphosphonates in knee osteoarthritis have yielded conflicting results. To learn more,…

Keeping the Pressure on Congress: ACR Opposes Medicare Payment Adjustment Plan, Executive Order

Angus Worthing, MD, FACP, FACR  |  October 19, 2017

Greetings, advocates! Here’s a brief, interim hodgepodge of updates to keep you posted on government advocacy before the deluge of information swamps you in San Diego. The Next Big Thing: Part B Drug Reimbursements Medicare currently plans to adjust reimbursement of doctors in the MIPS program in 2019, not only based on E/M office services,…

ACR Works to Eliminate Part B Drug Costs from MIPS Payment Adjustments

Kelly Tyrrell  |  October 19, 2017

The ACR is taking steps to clarify a proposed rule from the Centers for Medicare and Medicaid Services (CMS) that, as currently written, would consider the cost of Part B drugs when calculating physician reimbursement under the Merit-Based Incentive Payment System (MIPS). “The ACR is concerned about this, because large cuts to reimbursement for pass-through…

Final Quarter for 2017 MIPS Reimbursement Has Begun

From the College  |  October 19, 2017

The final stage of reporting for the Merit-Based Incentive Payment System (MIPS) began Oct. 2, 2017, if you chose the option to report for 90 consecutive days. The MIPS transition year began Jan. 1, 2017, and runs until Dec. 31, 2017. If you subscribed to the Centers for Medicare & Medicaid Services’ (CMS) email, you…

Advocacy in the Social Media Era

From the College  |  October 19, 2017

Advocacy efforts in the medical profession are evolving as technology evolves. The rise of social media, in particular, has brought about great change in the way organizations, such as the ACR, interact with Congress. At the 2017 ACR/ARHP Annual Meeting, Nov. 3–8 in San Diego, former Sen. Tim Hutchinson (R-Ark.) will discuss how to continue…

  • « Previous Page
  • 1
  • …
  • 386
  • 387
  • 388
  • 389
  • 390
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences